Neoadjuvant Pazopanib in Renal Cell Carcinoma

Inclusion Criteria: * Age ≥ 18 years with radiographic evidence of nonmetastatic renal cell carcinoma * Histological verification of clear cell renal cell carcinoma (-Clinical stage 2 (7 cm) or greater with localized disease * No evidence of extranodal metastatic disease * Appropriate candidate for surgery * The Eastern Cooperative Oncology Group (ECOG) Performance status of 0-1 * Adequate organ function * Serum calcium, magnesium, potassium within normal limits, or if outside of normal limits, must be deemed clinically insignificant by the Investigator. * No known coagulopathy * Ability to read and follow instructions * Women of childbearing potential must have a negative serum pregnancy test performed within 14 days prior to the start of pazopanib treatment and both men and women must be willing to use adequate contraception. * Able to provide written, informed consent * Blood and urine samples must be provided from all subjects for biomarker analysis before and during treatment with pazopanib Exclusion Criteria * Known or suspected allergy to pazopanib * Inability to swallow or retain oral medication * Prior malignancy Exception: Subjects who have had another malignancy and have been disease-free for three years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible. * Unable or unwilling to discontinue use of prohibited medications at least 7 days prior to the first dose of study drug and for the duration of the study. * Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including * History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. * History of any one or more cardiovascular conditions within the past 6 months * Hypertension \[defined as systolic blood pressure (SBP) of ≥140 mmHg OR diastolic blood pressure (DBP) of ≥ 90 mmHg in spite of optimal medical management. * Evidence of active bleeding or bleeding diathesis. * Any serious and/or unstable pre-existing medical (especially hepatic disease), psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures. * Prior major surgery or trauma within 28 days prior to first dose of pazopanib and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major). * Pregnant or breastfeeding; breastfeeding may not resume for 14 days after the last dose of pazopanib * Prior treatment with any of the following anti-cancer therapies for treatment of their RCC: * radiation therapy, surgery or tumor embolization * chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy * Baseline Corrected QT Interval (QTc) \>480 msec or other clinically significant baseline ECG abnormality